Biosimilar adoption looks straightforward on paper: replace a reference biologic with a clinically equivalent, lower-cost alternative. In reality, conversions succeed or fail based on what happens between the formulary decision and the patient's next refill.
Even when the clinical case is strong, conversion can stall if a provider is hesitant to change a patient who's stable on therapy, if a patient is unclear about what the switch means, or if a pharmacy isn't prepared to manage it smoothly. The result isn't just confusion, it's members reverting to the reference product or moving to a higher-cost biologic with no biosimilar alternative, undoing any benefit the switch was meant to provide.
What separates conversions that hold from ones that don't usually comes down to four things: clear communication with the prescriber before the change takes effect, advance notice and support for the dispensing pharmacy, early and specific communication with the patient about what's changing and why, and follow-up monitoring after the switch to catch disruption early rather than after a patient has already abandoned therapy.
The pattern shows up clearly in real conversions. In one Humira transition, members moved from over 90% reference-product use to under 15% in less than a year, with 75% of transitioned patients remaining on the biosimilar past six months. In a separate Stelara conversion, 100% of transitioned members remained on therapy at six months. The difference between those results and a stalled conversion wasn't the biosimilar itself, it was whether providers, patients, and pharmacies were coordinated through the change.
Clinical takeaway: a biosimilar is only as good as the transition supporting it. Confirm the patient is appropriate for conversion, communicate the switch directly rather than relying on the pharmacy to explain it, and build in a follow-up touchpoint in the weeks after the switch to confirm continuity before assuming the conversion succeeded.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.